Michel Komajda is a Past President of the European Society of Cardiology and of the French Cardiac Society.He was also chairperson of the congress programme committee ESC 2005-2006 and of the Global scientific Affairs (2010-2014).
He is an expert in heart failure management and chaired the working group on heart failure of the ESC, Euro Survey I and was a member of the writting committee of guidelines on the management of heart failure on two occasions.
he has been member of the steering committee, of the clinical endpont committee or DSMB of many heart failure clinical trials including SHIFT, CORONA, I PRESERVE, COMET, PARADIGM HF, CARMEN, EMPHESUS, RENAISSANCE, PARAGON.
He created the cardio genetic department in his university hosptial Pitie Salpetriere
He received the Heart Failure Association life time award in 2017.
He has written # 250 peer review articles in the highest profile peer review international journals.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease